<DOC>
	<DOCNO>NCT00435448</DOCNO>
	<brief_summary>The purpose study evaluate efficacy lonidamine ( 50mg , 150mg ) compare placebo subject symptomatic BPH .</brief_summary>
	<brief_title>Study Efficacy Safety Lonidamine Treatment Symptomatic Benign Prostatic Hyperplasia</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lonidamine</mesh_term>
	<criteria>Capable understand purpose risk study sign statement inform consent Male 5080 year age Presence LUTS ( low urinary tract symptom ) least 3 month Prostate volume measure TRUS ( transrectal ultrasound ) &gt; 30 cc Qmax &lt; 15 mL/sec measure uroflowmetry ( minimum 125 mL must void ) IPSS ( International prostate symptom score ) &gt; 12 PSA &gt; 1.0 ng/mL Must ensure consent use medically acceptable method contraception throughout entire study sexual partner childbearing potential Able comply prescribe treatment protocol evaluation Prior treatment BPH alphablockers and/or herbal supplement past 2 week ( alphablockers herbal supplement treatment BPH allow study ) . Prior treatment 5alphareductase inhibitor allow discontinue least 3 month prior enrollment . Prior surgery prostate ( except biopsy ; subject eligible enroll one month full recovery prostate biopsy . ) Current past evidence malignant disease prostate prostatic intraepithelial neoplasia ( subject PSA 4 10 ng/mL , prostate cancer must rule satisfaction Principal Investigator . Subjects PSA &gt; 10 ng/mL exclude . ) Active urinary tract infection ( UTI ) Active cardiac , renal hepatic disease evidence : 1 . Serum creatinine &gt; 1.8 mg/dL 2 . ALT AST &gt; 2.5x upper limit normal screen 3 . History active myocardial infarction , unstable cardiac arrhythmia stroke within 6 month prior screen 4 . Uncontrolled congestive heart failure Uncontrolled diabetes mellitus ( fast blood glucose &gt; 200 mg/dL ) Use systemic teriods reason ( systemic steroid usage allow study ) . Inhaled and/or topical steroid allow . Concurrent participation participation investigational drug study within past 30 day prior screen Concomitant disease condition could interfere conduct study , would opinion investigator , pose unnaceptabele risk subject</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Benign Prostatic Hyperplasia</keyword>
	<keyword>BPH</keyword>
	<keyword>Enlarged Prostate</keyword>
</DOC>